Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study In Adults With Moderate To Severe Dermatomyositis

Phase 2

Completed

Conditions: Dermatomyositis

Interventions: Drug: Placebo Arm
Drug: PF-06823859 low
Drug: PF-06823859 high

First Posted Date: 2017-06-09

Last Posted Date: 2023-09-14

Lead Sponsor: Pfizer

Target Recruit Count: 75

Registration Number: NCT03181893

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇺🇸
Brigham and Women's Hospital - CTH, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 37 locations

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Conditions: Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

First Posted Date: 2017-06-06

Last Posted Date: 2019-11-04

Lead Sponsor: Pfizer

Registration Number: NCT03178071

Locations: 🇺🇸
Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States
🇺🇸
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States

and more 40 locations

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

Phase 2

Completed

Conditions: Group B Streptococcal Infections

Interventions: Biological: Multivalent group B streptococcus vaccine
Biological: Placebo

First Posted Date: 2017-05-31

Last Posted Date: 2019-07-02

Lead Sponsor: Pfizer

Target Recruit Count: 365

Registration Number: NCT03170609

Locations: 🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸
Kentucky Pediatric / Adult Research, Bardstown, Kentucky, United States
🇺🇸
J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States

and more 1 locations

A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Glasdegib Therapeutic Exposure
Drug: Glasdegib Supra-therapeutic Exposure
Drug: Positive Control (Moxifloxacin)
Other: Placebo Control

First Posted Date: 2017-05-22

Last Posted Date: 2019-09-06

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT03162900

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Ibrance Real World Insights

Completed

Conditions: Malignant Neoplasm of Breast

First Posted Date: 2017-05-18

Last Posted Date: 2022-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 652

Registration Number: NCT03159195

Locations: 🇺🇸
Pfizer, Inc., New York, New York, United States

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Talazoparib

First Posted Date: 2017-05-11

Last Posted Date: 2024-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT03148795

Locations: 🇫🇷
Institut de Cancerologie Strasbourg Europe, Strasbourg, France
🇺🇸
Levine Cancer Institute-Lincolnton, Lincolnton, North Carolina, United States
🇦🇺
Intergrated Clinical Oncology Network (ICON), South Brisbane, Queensland, Australia

and more 115 locations

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Biological: PF-06730512

First Posted Date: 2017-05-09

Last Posted Date: 2018-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 79

Registration Number: NCT03146065

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

Terminated

Conditions: Metastatic Renal Cell Carcinoma

First Posted Date: 2017-05-04

Last Posted Date: 2024-05-10

Lead Sponsor: Pfizer

Target Recruit Count: 77

Registration Number: NCT03140176

Locations: 🇩🇿
Pierre Et Marie Curie Center, Algers, Algeria
🇩🇿
Hanene Djedi, Annaba, Algeria
🇪🇬
Demerdash Hospital, Cairo, Egypt

and more 5 locations

A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Crizotinib
Drug: Esomeprazole

First Posted Date: 2017-05-02

Last Posted Date: 2017-10-31

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT03137134

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Phase 3

Completed

Conditions: Meningococcal Vaccine

Interventions: Biological: rLP2086
Biological: MenABCWY
Biological: MenACWY-CRM
Biological: Saline

First Posted Date: 2017-05-01

Last Posted Date: 2023-08-08

Lead Sponsor: Pfizer

Target Recruit Count: 1610

Registration Number: NCT03135834

Locations: 🇺🇸
Optimal Research, LLC, Melbourne, Florida, United States
🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸
Clinical Research Consortium, Tempe, Arizona, United States

and more 61 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy